Logotype for Level Bio

Level Bio (LEVBIO) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Level Bio

Q3 2026 earnings summary

23 Oct, 2026

Executive summary

  • Q3 revenue rose 28% YoY to 8,644 KSEK; comparable growth excluding CyberGene was 59%, while gross margin fell to 40%.

  • Techtum Lab drove growth; priorities include Nordic expansion, portfolio development and profitability.

Financial highlights

  • Q3 revenue was 8,644 KSEK vs 6,750 KSEK; excluding CyberGene’s prior-year contribution, sales were 8,644 KSEK vs 5,432 KSEK, up 59%.

  • Q3 gross profit was 3,415 KSEK vs 3,787 KSEK; operating loss was 310 KSEK vs 207 KSEK, and net loss was 348 KSEK vs 164 KSEK.

  • 9M revenue rose 17% to 26,841 KSEK from 22,939 KSEK; growth was 31% excluding CyberGene. Gross profit was 12,452 KSEK.

  • 9M operating loss narrowed to 652 KSEK from 2,599 KSEK; result after financial items was 5,684 KSEK vs a loss of 2,649 KSEK, impacted by the disposal.

  • Q3 cash flow was -11 KSEK vs +16 KSEK YoY; 9M cash flow was -2,418 KSEK vs +496 KSEK.

Outlook and guidance

  • Strategy centers on Techtum Lab as a platform for profitable growth, growing distribution sales and reaching profitability.

  • Plans include establishing local presence across Nordic countries through hiring and/or acquisitions, and expanding sales in all Nordic markets.

  • Q4 priorities are sales execution, Nordic expansion and profitability; portfolio and pricing decisions will balance growth with margin.

  • CyberGene’s divestment creates comparison effects expected to persist through Q1 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Level Bio